The discovery of CALR mutations in JAK2/MPL-unmutated ET patients in December 2013 have prompted us to ask the question that whether increased B cell activation can also be found in ET with CALR mutations similar to that in JAK2V617F-mutated ET [7–9]. The gene discussed is JAK2; the disease is essential thrombocythemia.